Trending Now
Adptimmune Therapeutics Plc (NASDAQ: ADAP) Releases Encouraging Data From SURPASS Study...
Adptimmune Therapeutics Plc (NASDAQ: ADAP) has announced its latest data from the first phase SURPASS study in multiple solid tumors. The data will be...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
Gritstone Oncology Inc (NASDAQ:GRTS) Begins Phase 1 Clinical Study Of COVID-19...
Gritstone Oncology Inc (NASDAQ:GRTS) commenced the phase 1 clinical trial of its COVID-1 vaccine under Gritstone’s “CORAL” program by dosing the first person.
The company will...
MAKE IT MODERN
LATEST REVIEWS
Akebia Therapeutics Inc (NASDAQ:AKBA) Files NDA With The US FDA For...
Akebia Therapeutics Inc (NASDAQ:AKBA) filed an NDA (New Drug Application) for its Vadadustat with the US FDA to treat adult patients suffering from anemia...
MAKE IT MODERN
PERFORMANCE TRAINING
Trevena Inc (NASDAQ:TRVN) Collaborates with Imperial College London to Conduct a Proof-of-Concept Study for...
The presence of COVID-19 continues to be one of the trending topics across the world. However, efforts to bring forth a potential vaccine are...
ADMA Biologics Inc (NASDAQ:ADMA) Posts A Growth Of 19% In Q2 2020 Revenues
ADMA Biologics Inc (NASDAQ:ADMA) reported an increase of 19% YoY to $7.8 million in Q2 2020. It is mainly on the backdrop of increased...
Vir Biotechnology. (NASDAQ:VIR) and GlaxoSmithKline (NYSE:GSK) Announce Expansion Of Phase 3 COMET-ICE Study Of...
Vir Biotechnology Inc. (NASDAQ:VIR) and GlaxoSmithKline Plc (NYSE:GSK) have announced the expansion of the global Phase 3 COMET-ICE (COVID-19 Monoclonal antibody Efficacy Trial –...
Zeeland Pharma A/S (NASDAQ: ZEAL) Doses First Subject in Phase 3b Study Evaluating Glepaglutide...
Zeeland Pharma A/S (NASDAQ: ZEAL) has announced the dosing of the first participants in the Phase 3b study, EASE-SBS 4, assessing glepaglutide, a long-acting...
Biotech Stocks Take Centerstage as Markets Turn Red (COEP,AMLX, BMRN, EXEL, HALO, INVA, MDXG,...
Many experts suggest that we're currently experiencing a renaissance in biotechnology. The field is undergoing revolutionary transformations, unlocking novel methods to combat...
MAKE IT MODERN
